[go: up one dir, main page]

ECSP18079073A - Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos - Google Patents

Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos

Info

Publication number
ECSP18079073A
ECSP18079073A ECSENADI201879073A ECDI201879073A ECSP18079073A EC SP18079073 A ECSP18079073 A EC SP18079073A EC SENADI201879073 A ECSENADI201879073 A EC SENADI201879073A EC DI201879073 A ECDI201879073 A EC DI201879073A EC SP18079073 A ECSP18079073 A EC SP18079073A
Authority
EC
Ecuador
Prior art keywords
antigens
methods
compositions
chagas
antibodies
Prior art date
Application number
ECSENADI201879073A
Other languages
English (en)
Inventor
Gregory Stoloff
Wilson Caparros-Wanderley
Mateo Olga Pleguezuelos
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of ECSP18079073A publication Critical patent/ECSP18079073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente memoria descriptiva describe antígenos, composiciones inmunogénicas de Trypanosoma y medicamentos que comprenden dichos antígenos de Trypanosoma, métodos y usos para tales antígenos y composiciones inmunogénicas de Trypanosoma para tratar una enfermedad basada en Trypanosoma.
ECSENADI201879073A 2016-04-14 2018-10-19 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos ECSP18079073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14

Publications (1)

Publication Number Publication Date
ECSP18079073A true ECSP18079073A (es) 2019-02-28

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201879073A ECSP18079073A (es) 2016-04-14 2018-10-19 Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos

Country Status (18)

Country Link
US (2) US10973897B2 (es)
EP (1) EP3442569A1 (es)
JP (1) JP2019513797A (es)
KR (1) KR20190039022A (es)
CN (2) CN109310747B (es)
AU (1) AU2017248680A1 (es)
BR (1) BR112018071108A2 (es)
CA (1) CA3020856A1 (es)
CL (2) CL2018002932A1 (es)
CO (1) CO2018012295A2 (es)
CU (1) CU20180127A7 (es)
EC (1) ECSP18079073A (es)
MX (1) MX2018012504A (es)
NI (1) NI201800105A (es)
PE (1) PE20190104A1 (es)
RU (1) RU2018139865A (es)
SG (1) SG11201808915YA (es)
WO (1) WO2017178660A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144465A1 (en) * 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine
WO2020144464A1 (en) 2019-01-07 2020-07-16 Genome Research Limited Novel trypanosomal vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
FR2952382B1 (fr) * 2009-11-10 2011-11-25 Univ Victor Segalen Bordeaux 2 Vaccins et diagnostics contre les trypanosomoses animales africaines
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112015032978B1 (pt) 2013-07-02 2022-08-16 Institut De Recherche Pour Le Développement Método de diagnóstico para a detecção de anticorpos indicativos de leishmania sul americana e kit de diagnóstico para detecção de anticorpos antileishmaniose
US9566320B2 (en) * 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
NI201800105A (es) 2019-02-18
CU20180127A7 (es) 2019-08-06
CO2018012295A2 (es) 2019-04-30
CN109310747A (zh) 2019-02-05
EP3442569A1 (en) 2019-02-20
CN116059330A (zh) 2023-05-05
MX2018012504A (es) 2019-08-29
KR20190039022A (ko) 2019-04-10
US20170296637A1 (en) 2017-10-19
CN109310747B (zh) 2022-11-22
SG11201808915YA (en) 2018-11-29
BR112018071108A2 (pt) 2019-02-26
AU2017248680A1 (en) 2018-11-22
CL2021001441A1 (es) 2021-11-19
US20210220453A1 (en) 2021-07-22
WO2017178660A1 (en) 2017-10-19
RU2018139865A (ru) 2020-05-14
CA3020856A1 (en) 2017-10-19
CL2018002932A1 (es) 2019-02-01
US10973897B2 (en) 2021-04-13
JP2019513797A (ja) 2019-05-30
PE20190104A1 (es) 2019-01-15
WO2017178660A9 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
AR102657A1 (es) Composición para tratar telas
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
MX383227B (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
MX2017015725A (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
MX2015016627A (es) Vacuna para la malaria.
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
CL2016002469A1 (es) Sulfamidasa modificada y su producción
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
ECSP18079073A (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
CR20160389A (es) Terapias dirigidas
BR112019000706A2 (pt) agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
ES1210064Y (es) Cápsula monodosis para biberón